Loading...
Market
Will Marea Therapeutics initiate a Phase 1 clinical trial by June 18, 2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov, company press releases
Story
Third Rock-backed Marea Therapeutics Launches with $190M to Tackle Cardiometabolic Diseases Targeting ANGPTL4
Jun 18, 2024, 11:49 AM
Marea Therapeutics has launched with $190 million in funding to develop new treatments for cardiometabolic diseases. The biotech company, which focuses on leveraging large-scale human genetics and adipose biology, aims to address the lingering issue of high cholesterol and cardiovascular disease. Founded by Ethan Weiss and led by CEO Josh Lehrer, Marea targets the ANGPTL4 gene, which has been linked to cardiometabolic disease but has not attracted much interest from the pharmaceutical industry due to safety concerns. The Third Rock-backed, 10-person startup plans to use its funding to pioneer the next frontier of cardiometabolic medicines and improve patient outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%